Optical colposcope developer raises $25M towards growth needs

The colposcope uses optical and software techniques to scan a patient’s cervix, quantify the results, and present them to a clinician.

Optical molecular imaging technologies developer DYSIS Medical (Edinburgh, Scotland) has completed a $25 million (£18 million) investment to help accelerate growth of its DYSIS Ultra colposcope used in cervical cancer screening.

The colposcope uses optical and software techniques to scan a patient’s cervix, quantify the results, and present them to a clinician in the form of an intuitive color-coded map (DYSISmap). The map can be easily shown and explained during an examination, improving understanding and reducing anxiety.

Within the past year, the company has launched its latest-generation DYSIS Ultra colposcope, published updated guidance recommending the adoption of the colposcope by the National Health Service (NHS), and published compelling U.S. clinical data showing that the colposcope detected in excess of 40% more women with cervical disease requiring treatment, who would have been missed by conventional methods.

DYSIS Medical CEO Alastair Atkinson says that the investment funds will be used to continue expansion in the U.S., UK, and other key territories, in addition to advancing strategic R&D programs.

For more information, please visit www.dysismedical.com.

More in Bioimaging